JNK-IN-7: Selective Covalent JNK Inhibitor for MAPK Pathway & Apoptosis Research

Executive Summary: JNK-IN-7 is a covalent, highly selective inhibitor of c-Jun N-terminal kinases (JNK1-3), with IC₅₀ values of 1.54 nM (JNK1), 1.99 nM (JNK2), and 0.75 nM (JNK3). It acts by covalently binding to Cys116 in JNK2, irreversibly inhibiting kinase activity and subsequent c-Jun phosphorylation (APExBIO). JNK-IN-7 also modulates IRAK-1/Pellino 1-dependent Toll receptor signaling at higher concentrations, affecting innate immune responses. Its robust selectivity and solubility profile make it a preferred tool in studies of MAPK signaling, inflammation, and apoptosis (Miao et al., 2023). Experimental best practices require fresh DMSO-based solutions and storage at -20°C to preserve stability.

Biological Rationale

The JNK (c-Jun N-terminal kinase) family is central to signal transduction in stress, inflammatory, and apoptotic processes. JNKs are serine/threonine kinases within the MAPK (mitogen-activated protein kinase) superfamily. Their activation leads to phosphorylation of c-Jun and other downstream targets, modulating gene expression relevant to cell death, survival, and immune responses (Miao et al., 2023).

Recent research, such as the study by Miao et al. (2023), demonstrates the pivotal role of JNK and ERK pathways in regulating apoptosis of bovine mammary epithelial cells (BMECs) upon fungal challenge. In the context of Candida krusei infection, both yeast and hypha phases induce BMEC apoptosis via TLR2/ERK and JNK/ERK signaling, highlighting the importance of precision kinase inhibitors for pathway dissection (DOI).

Mechanism of Action of JNK-IN-7

JNK-IN-7 is a small-molecule, irreversible covalent inhibitor. It selectively targets JNK1, JNK2, and JNK3 isoforms with high potency (IC₅₀ values: 1.54 nM, 1.99 nM, 0.75 nM, respectively) (APExBIO). The mechanism involves covalent modification of a cysteine residue (Cys116) in JNK2, blocking ATP binding and kinase activity. This results in the inhibition of downstream phosphorylation of c-Jun, a direct substrate of JNK (related article).

At higher concentrations (1–10 μM), JNK-IN-7 also impedes IRAK-1-dependent E3 ubiquitin ligase activity of Pellino 1, a critical component in Toll-like receptor (TLR) signaling. This action broadens its utility to innate immune modulation in experimental cell systems such as human IL-1R and RAW264.7 macrophages (see contrast: broader immunomodulatory context).

Evidence & Benchmarks

• JNK-IN-7 exhibits sub-nanomolar inhibition of JNK1, JNK2, and JNK3 in biochemical kinase assays (IC₅₀: 1.54, 1.99, 0.75 nM, respectively) (APExBIO).
• It covalently modifies Cys116 in JNK2, leading to irreversible inhibition of kinase activity (JNK-IN-7: Selective Covalent JNK Inhibitor for MAPK Pathways).
• In cellular models, JNK-IN-7 suppresses c-Jun phosphorylation, validated via Western blot in both human and rodent cells (extends: practical evidence for c-Jun inhibition).
• JNK-IN-7 at 1–10 μM inhibits IRAK-1/Pellino 1 E3 ligase activity, modulating TLR pathway signaling in innate immune cells (strategic insight reference).
• BMEC apoptosis induced by C. krusei is regulated by both the TLR2/ERK and JNK/ERK pathways, indicating JNK-IN-7’s investigative value for dissecting these axes (Miao et al., 2023, Table 2).
• JNK-IN-7 is soluble at ≥24.7 mg/mL in DMSO, but insoluble in water and ethanol; it must be freshly prepared for experimental use (APExBIO).

Applications, Limits & Misconceptions

JNK-IN-7 is validated for use in studies focusing on the MAPK signaling pathway, apoptosis assays, and innate immune signaling modulation. Its high selectivity makes it suitable for dissecting c-Jun N-terminal kinase pathway roles in cell models of inflammation and programmed cell death (clarifies: preferred reagent status and workflow best practices).

Recent translational research leverages JNK-IN-7 to explore the molecular mechanisms of pathogen-induced apoptosis, such as in bovine mastitis models. For example, Miao et al. (2023) demonstrated that JNK/ERK pathway inhibition can delineate the distinct apoptosis mechanisms induced by yeast and hyphal forms of C. krusei (Animals 2023, 13, 3222).

Common Pitfalls or Misconceptions

• JNK-IN-7 is not selective for all MAPKs: It targets JNK1-3, but does not broadly inhibit ERK or p38 pathways (APExBIO).
• Not suitable for aqueous buffers: Compound is insoluble in water and ethanol; DMSO is required for solubilization.
• Long-term stock solutions are unstable: Working solutions must be freshly prepared; storage at -20°C is essential for solid form only.
• Off-target IRAK-1/Pellino 1 inhibition occurs only at higher concentrations (1–10 μM): Lower concentrations are preferred for JNK-specific effects.
• Does not directly block upstream kinases or non-JNK MAPK modules: Use with caution when interpreting pathway-wide effects.

Workflow Integration & Parameters

JNK-IN-7 should be handled as a solid at -20°C. For experimental use, dissolve in DMSO at concentrations up to 24.7 mg/mL. Solutions should be freshly prepared immediately prior to use to maintain potency. Typical cell-based assays employ concentrations from 10 nM to 10 μM, depending on the desired selectivity (JNK vs. IRAK-1/Pellino 1 effect). Avoid aqueous or ethanol-based solvents due to insolubility (see product details).

APExBIO supplies JNK-IN-7 (SKU: A3519) as a high-purity solid. Refer to product documentation for specific batch QC data and recommended workflow protocols (APExBIO).

Conclusion & Outlook

JNK-IN-7 is a rigorously validated, selective covalent JNK kinase inhibitor, supporting high-specificity research in MAPK pathway biology, apoptosis, and innate immune modulation. Its robust biochemical and cell-based performance make it a key tool for dissecting the complexity of c-Jun N-terminal kinase signaling in both health and disease contexts. Continued integration into translational research—especially for inflammation and infection models—will further clarify its impact and optimal deployment strategies. For additional mechanistic context or experimental design guidance, see the extended discussion in JNK-IN-7: Mechanistic Precision and Strategic Impact (contrasts with this article by focusing on translational laboratory strategies).